Potential interaction of troglitazone and cyclosporine

被引:29
作者
Kaplan, B [1 ]
Friedman, G [1 ]
Jacobs, M [1 ]
Viscuso, R [1 ]
Lyman, N [1 ]
DeFranco, P [1 ]
Bonomini, L [1 ]
Mulgaonkar, SP [1 ]
机构
[1] St Barnabas Med Ctr, Dept Renal & Transplant, Livingston, NJ 07039 USA
关键词
D O I
10.1097/00007890-199805270-00021
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Troglitazone (Rezulin) is a promising new oral hypoglycemic agent recently approved by the Federal Drug Administration for use in type II diabetes mellitus. Although troglitazone is not metabolized by the cytochrome p450 3A isozyme family, it is a potential inducer of this system, Other medications, e.g., rifampin and phenobarbital, which also induce p450 3A activity, have been reported to significantly decrease cyclosporine (CsA) concentrations. Methods. We report a case of a stable renal transplant patient who had a decrease in CsA concentration after beginning troglitazone and who subsequently developed an acute rejection episode. We then reviewed all stable renal patients begun on troglitazone over the previous 6 months. Results. The seven transplant patients who had been started on troglitazone therapy experienced a statistically and clinically significant decrease in CsA 12-hr trough levels immediately after the institution of troglitazone therapy. Conclusion. A potential interaction exists between troglitazone and CsA. Transplant patients on CsA who receive troglitazone therapy should be monitored closely.
引用
收藏
页码:1399 / 1400
页数:2
相关论文
共 8 条
[1]   THE EFFECTS OF KETOCONAZOLE ON THE INTESTINAL METABOLISM AND BIOAVAILABILITY OF CYCLOSPORINE [J].
GOMEZ, DY ;
WACHER, VJ ;
TOMLANOVICH, SJ ;
HEBERT, MF ;
BENET, LZ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 58 (01) :15-19
[2]   BIOAVAILABILITY OF CYCLOSPORINE WITH CONCOMITANT RIFAMPIN ADMINISTRATION IS MARKEDLY LESS THAN PREDICTED BY HEPATIC ENZYME-INDUCTION [J].
HEBERT, MF ;
ROBERTS, JP ;
PRUEKSARITANONT, T ;
BENET, LZ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 52 (05) :453-457
[3]   Effect of troglitazone (CS-045) and bezafibrate on glucose tolerance, liver glycogen synthase activity, and beta-oxidation in fructose-fed rats [J].
Inoue, I ;
Takahashi, K ;
Katayama, S ;
Harada, Y ;
Negishi, K ;
Itabashi, A ;
Ishii, J .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1995, 44 (12) :1626-1630
[4]  
KEOWN PA, 1982, TRANSPLANT P, V14, P659
[5]   PHARMACOKINETICS AND TOLERABILITY OF A MICROEMULSION FORMULATION OF CYCLOSPORINE IN RENAL-ALLOGRAFT RECIPIENTS - A CONCENTRATION-CONTROLLED COMPARISON WITH THE COMMERCIAL FORMULATION [J].
MUELLER, EA ;
KOVARIK, JM ;
VANBREE, JB ;
LISON, AE ;
KUTZ, K .
TRANSPLANTATION, 1994, 57 (08) :1178-1182
[6]  
*PARK PHARM LTD, 1997, REZ TROGL TABL
[7]   DIFFERENTIATION OF ABSORPTION AND FIRST-PASS GUT AND HEPATIC-METABOLISM IN HUMANS - STUDIES WITH CYCLOSPORINE [J].
WU, CY ;
BENET, LZ ;
HEBERT, MF ;
GUPTA, SK ;
ROWLAND, M ;
GOMEZ, DY ;
WACHER, VJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 58 (05) :492-497
[8]  
YEE GC, 1986, APPL THERAPEUTICS